AI / data analytics / healthtech / informatics

#AI / data analytics / healthtech / informatics #Alzheimer's #Automation #Biomarkers #Data automation #Data management #Digital biomarkers #Digitalisation #Drug development #Drug discovery #Genetics / genomics #Mass spectrometry / NMR #Neurodegenerative disorders #Neuroscience

New podcast: The far-reaching impact of drug discovery technology

This is the latest episode of the free DDW narrated podcast, titled “The far-reaching impact of drug discovery technology”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Accelerating time to market through digitalisation”, “… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial #Clinical trial design #Phesi

Over collection of data delays clinical trials, report finds

A significant number of Phase III clinical trials are over-collecting data because of overcomplicated protocol designs, leading to avoidable delays in drug development times, says a new report.  Phesi used proprietary data from its Trial Accelerator Platform to analyse 2,401 industry-sponsored Phase III clinical trials that have… Read More

#News

#AI / data analytics / healthtech / informatics #Data management #Laboratory data

Revealing the big data picture in drug discovery

This article is sponsored by CAS. Jacob Al-Saleem, PhD, Senior Data Scientist at CAS, explains why it is important to take a data-first approach when building predictive models for drug discovery. Since the early 2000s, big tech companies have been compiling and analysing user data to not only track behaviour… Read More

#Exclusive Content

High content screening
#AI / data analytics / healthtech / informatics #High Content Screening #Imaging

Accelerating drug discovery: The impact of ultra-fast screening

This paid-for advertorial by Araceli Biosciences appeared in DDW Volume 25 – Issue 4, Fall 2024 Read the digital issue Accelerating discovery with real-time laboratory data  In the era of artificial intelligence (AI), biotech R&D is hungry for data like never before. Machine learning (ML) is transforming innovation: faster discovery, better designs,… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Business #Digital solutions #Digital workflow #Drug development #Drug discovery #EMA #FDA #Marketing #Pharmaceuticals #Regulatory

New podcast: How to streamline regulatory approval

This is the latest episode of the free DDW narrated podcast, titled “How to streamline regulatory approval”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Quicker time to regulatory submission through improved data management and The three key stages to… Read More

#News #Regulatory

AI roadmap
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Large language model (LLM) #Machine learning

Unlocking AI in drug discovery: A roadmap to scalable solutions

Dr Mutlu Dogruel, Vice President of AI Solutions at Cresset, examines AI’s transformative potential, highlights the current challenges and introduces a series of potential solutions to implement AI in the drug discovery landscape successfully. The use of artificial intelligence (AI) is creating a paradigm shift in drug discovery and optimisation… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Automated workflows #Automation #Automation / robotics #Biopharma #Biopharmaceuticals #Data science #Drug development #Drug discovery #Lab automation #Lab technology #Personalised medicine #Pharmaceuticals

New podcast: How technology is impacting drug discovery

This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI is critical to solving new complexities in drug discovery and… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug repurposing #Partnership #Rejuvenate Biomed

Rejuvenate Bio and SAS to develop drug repurposing tool

Biotechnology company Rejuvenate Biomed has announced a partnership with analytics company SAS to develop a drug repurposing discovery tool to help researchers and scientists uncover medically relevant insights about drugs, diseases, and biological networks. The tool will be developed using SAS’ artificial intelligence (AI) and data platform, Viya. It will… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Biotech #Drug development #Drug discovery

Rethinking the pharma R&D lifecycle with AI in mind

Ashu Singhal and Sajith Wickramasekara, co-founders of Benchling, explore how AI's true promise for the pharmaceutical industry can only be realised if the entire pharmaceutical R&D lifecycle is supported. Drug discovery has quickly become a trendy place to apply AI. Billions of dollars are being invested in AI-driven techbios and… Read More

#Exclusive Content

Handshake jigsaw puzzle
#AI / data analytics / healthtech / informatics #Collaboration #Lab space #Lab technology #Partnership #Sapio Sciences #Zifo

Industry players partner to provide lab informatics  

Sapio Sciences and Zifo have announced a strategic partnership to bring best-in-class laboratory information management solutions to customers across the biotech, clinical diagnostics, and pharmaceutical industries.  Zifo will join the Sapio Sciences Partner Program as a services partner, focusing on delivering solutions that combine Zifo’s IT services… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Briefly Bio #Financing #Software

AI data sharing company Briefly Bio launches with $1.2m funding

Briefly Bio, a software company that hopes to make lab work more reproducible by helping scientists capture and share their work, has launched with a $1.2m pre-seed funding round. The financing was led by Compound VC, with participation from NP Hard, Tiny VC and angel investors across tech and biotech. Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Generative AI #Regulatory

Adding value to regulatory intelligence with generative AI

There is limitless scope for generative AI to transform regulatory processes. But where to start? ArisGlobal’s Agnes Cwienczek and Renato Rjavec describe use cases where AI is already delivering tangible everyday benefits. As life sciences companies’ investments in regulatory data capture, enrichment and exchange continue to rise in line with… Read More

#Exclusive Content #Regulatory

A team working in a laboratory
#AI / data analytics / healthtech / informatics #Collaboration #Contract Research Organisations (CROs) #Drug discovery #Webinar

Connecting teams and designsets across the DMTA cycle

This paid-for advertorial by Cresset appeared in DDW Volume 25 – Issue 3, Summer 2024. Earlier this year, DDW hosted a webinar, ‘Enhancing collaboration in drug discovery – a biotech perspective’, supported by Cresset. The event emphasised the importance of creating a solid infrastructure within any discovery project to enable close… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Machine learning #PhaseV

ML could facilitate increased adoption of adaptive clinical trials

A new machine learning (ML) software platform has been launched to facilitate wider adoption of advanced and adaptive clinical trials. The latest version of AdaptV includes an advanced mode to support more in-depth modifications of relevant algorithmic and statistical parameters that go into trial design, accounting… Read More

#News

Brain Awareness Week
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trial design #Machine learning

How large language models can elevate clinical research

Deepika Khedekar investigates the use of LLMs in clinical trials and how we can overcome the potential challenges to their wider application. $2.3 billion1 is the estimated cost of bringing a new drug from the drawing board to pharmacy shelves today. Clinical trials make up a large part of this investment,… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Anti-inflammatory #Artificial intelligence (AI) #Cancer research #Covid-19 #EpicentRx #Immunology / Virology & Vaccines #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

New podcast on the significance of drug repurposing

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack… Read More

#News